Legend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Conference Call November 20, 2023 8:00 AM ET

Company Participants

Jessie Yeung - Head of Investor Relations and Public Relations

Ying Huang - Chief Executive Officer

Lori Macomber - Chief Financial Officer

Steve Gavel - Senior Vice President, Commercial Development, Us and Europe

Guowei Fang - Chief Scientific Officer and Head of Business Development

Conference Call Participants

Gena Wang - Barclays

Jessica Fye - JPM Chase

Kelly Shi - Jefferies

Vikram Purohit - Morgan Stanley

Leonid Timashev - RBC Capital Markets

Yaron Werber - TD Cowen

Linhai Zhao - Goldman Sachs

Jonathan Miller - Evercore ISI

Ashwani Verma - UBS

Kostas Biliouris - BMO Capital Markets

Justin Zelin - BTIG

Mitchell Kapoor - H.C. Wainwright

Wilfred Yuen - Daiwa

Kelsey Goodwin - Guggenheim

Sami Corwin - William Blair

Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today's conference may be recorded.

I will now hand the conference over to your speaker host, Jessie Yeung, Head of Investor Relations and Public Relations. You may begin.

Jessie Yeung

Good morning. This is Jessie Yeung, Head of Investor Relations and Public Relations at Legend Biotech. Thank you for joining our conference call today to review our third quarter 2023 performance.

Joining me on today's call are Ying Huang, the company's Chief Executive Officer and Lori Macomber, the company's Chief Financial Officer. Following the prepared remarks, we will open up the call for a Q&A. We will be joined by Guowei Fang, Chief Scientific Officer and Steve Gavel, Head of Commercial Development for the US and Europe.

During today's call, we will be making forward-looking statements, which are subject to risks and uncertainties that may cause our actual results to differ materially from those expressed or implied here within. These forward-looking statements are discussed in greater detail in our SEC filings, which we encourage you to read and can be found under the Investors section of our company website. Thank you.

I will now turn the call over to Ying.

Ying Huang

Good morning and thank you for joining us today to discuss the third quarter financial and corporate accomplishments of Legend Biotech. We are pleased with the progress we have made over the last quarter to advance our portfolio and pipeline of innovative therapies that are focused on addressing the serious and intractable disease patients face.